Market Cap 541.29M
Revenue (ttm) 35.28M
Net Income (ttm) -169.03M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -479.11%
Debt to Equity Ratio 0.00
Volume 268,200
Avg Vol 272,192
Day's Range N/A - N/A
Shares Out 69.31M
Stochastic %K 18%
Beta 1.47
Analysts Strong Sell
Price Target $24.90

Company Profile

Bicycle Therapeutics plc, a clinical-stage pharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. The company's products pipeline include zelenectide pevedotin, a bicycle toxin conjugate (BTC), which is in phase I/II/III clinical trials for the treatment of high nectin-4 expressing tumors; BT5528 (EphA2), a BTC that is in phase I/II clinical trials to treat Ephrin type A receptor 2 expressing t...

Industry: Biotechnology
Sector: Healthcare
Phone: 44 1223 261 503
Address:
Portway Building, Blocks A & B Granta Park Great Abington, Cambridge, United Kingdom
Damian23
Damian23 Oct. 23 at 4:10 PM
$BCYC Shares outstanding: As of August 2025, total shares outstanding are 69.3 million (49.87M ordinary + 19.44M non-voting).​ Peak Sales by 2028/29: TAM: ~85,000 metastatic urothelial cancer (UC) patients (US+EU).​ SAM: ~30,000 patients cisplatin-ineligible/previously treated.​ Conservative price: $100,000/year per patient (lower than aggressive ADC pricing). Market share estimate: 20% for zelenectide vs competitors.​ Peak sales = 30,000 × $100,000 × 0.20 = $600 million. Company cash: $721.5 million cash as of June 30, 2025, supporting runway into 2028.​ Debt: Minimal debt, clean balance sheet reported. Partnerships: CDMOs engaged for scalable production, no reported manufacturing constraints. Cash burn: Approximate burn rate annualized near $360 million, manageable with current cash.​ Fair EV/Sales multiple: Select conservative 5x given competitive field and early regulatory stage.​ Enterprise Value (peak): $600 million × 5 = $3.0 billion EV at peak sales.
2 · Reply
LabPsycho
LabPsycho Oct. 19 at 12:41 AM
$BCYC IMO, Market cap should decrease below 1/2 cash (extrapolated ahead to be current, not using prior quarter's numbers which tend to be almost 5 months in arrears for most biotech), + tax loss selling + blah biotech market - I can see this getting close to the 5's by December.
1 · Reply
S_Franconi
S_Franconi Oct. 18 at 1:50 PM
$BCYC Roger Dansey, M.D. & Hervé Hoppenot https://investors.bicycletherapeutics.com/news-releases/news-release-details/bicycle-therapeutics-strengthens-board-directors-new
0 · Reply
eladfff
eladfff Oct. 15 at 6:06 PM
$BCYC This is a pretty pretty pretttaaay good market for reporting anything positive... The market is rewarding good news with dramatic and sustained moves like you rarely see. Just sayin', BCYC mgmnt....
1 · Reply
Strangperson
Strangperson Oct. 9 at 7:39 PM
$BCYC when $20?
0 · Reply
eladfff
eladfff Oct. 7 at 6:17 PM
$BCYC At some point you actually have to give the market something positive if you want to ever support your share price. Has arguably been YEARS since there was a meaningful piece of positive news from the company.
1 · Reply
JarvisFlow
JarvisFlow Oct. 3 at 4:43 PM
Needham updates rating for Bicycle Therapeutics ( $BCYC ) to Buy, target set at 30 → 29.
0 · Reply
Fred378
Fred378 Oct. 2 at 2:35 PM
$BCYC long term
0 · Reply
rxptgh
rxptgh Oct. 2 at 12:34 PM
$BCYC very
1 · Reply
kclan
kclan Oct. 1 at 7:22 PM
$BCYC Likey likey!
0 · Reply
Latest News on BCYC
Bicycle Therapeutics Is Looking Increasingly Attractive

Aug 20, 2024, 7:37 AM EDT - 1 year ago

Bicycle Therapeutics Is Looking Increasingly Attractive


2 More Potential Biotech Buyout Targets

Mar 25, 2024, 1:07 PM EDT - 1 year ago

2 More Potential Biotech Buyout Targets

AZN BMY EXEL LLY MRK NVS TAK


Bicycle Therapeutics to Host R&D Day on December 14

Nov 30, 2023, 7:00 AM EST - 2 years ago

Bicycle Therapeutics to Host R&D Day on December 14


Damian23
Damian23 Oct. 23 at 4:10 PM
$BCYC Shares outstanding: As of August 2025, total shares outstanding are 69.3 million (49.87M ordinary + 19.44M non-voting).​ Peak Sales by 2028/29: TAM: ~85,000 metastatic urothelial cancer (UC) patients (US+EU).​ SAM: ~30,000 patients cisplatin-ineligible/previously treated.​ Conservative price: $100,000/year per patient (lower than aggressive ADC pricing). Market share estimate: 20% for zelenectide vs competitors.​ Peak sales = 30,000 × $100,000 × 0.20 = $600 million. Company cash: $721.5 million cash as of June 30, 2025, supporting runway into 2028.​ Debt: Minimal debt, clean balance sheet reported. Partnerships: CDMOs engaged for scalable production, no reported manufacturing constraints. Cash burn: Approximate burn rate annualized near $360 million, manageable with current cash.​ Fair EV/Sales multiple: Select conservative 5x given competitive field and early regulatory stage.​ Enterprise Value (peak): $600 million × 5 = $3.0 billion EV at peak sales.
2 · Reply
LabPsycho
LabPsycho Oct. 19 at 12:41 AM
$BCYC IMO, Market cap should decrease below 1/2 cash (extrapolated ahead to be current, not using prior quarter's numbers which tend to be almost 5 months in arrears for most biotech), + tax loss selling + blah biotech market - I can see this getting close to the 5's by December.
1 · Reply
S_Franconi
S_Franconi Oct. 18 at 1:50 PM
$BCYC Roger Dansey, M.D. & Hervé Hoppenot https://investors.bicycletherapeutics.com/news-releases/news-release-details/bicycle-therapeutics-strengthens-board-directors-new
0 · Reply
eladfff
eladfff Oct. 15 at 6:06 PM
$BCYC This is a pretty pretty pretttaaay good market for reporting anything positive... The market is rewarding good news with dramatic and sustained moves like you rarely see. Just sayin', BCYC mgmnt....
1 · Reply
Strangperson
Strangperson Oct. 9 at 7:39 PM
$BCYC when $20?
0 · Reply
eladfff
eladfff Oct. 7 at 6:17 PM
$BCYC At some point you actually have to give the market something positive if you want to ever support your share price. Has arguably been YEARS since there was a meaningful piece of positive news from the company.
1 · Reply
JarvisFlow
JarvisFlow Oct. 3 at 4:43 PM
Needham updates rating for Bicycle Therapeutics ( $BCYC ) to Buy, target set at 30 → 29.
0 · Reply
Fred378
Fred378 Oct. 2 at 2:35 PM
$BCYC long term
0 · Reply
rxptgh
rxptgh Oct. 2 at 12:34 PM
$BCYC very
1 · Reply
kclan
kclan Oct. 1 at 7:22 PM
$BCYC Likey likey!
0 · Reply
rxptgh
rxptgh Sep. 29 at 8:58 PM
$BCYC biotechs have been giving me Nightmares like a dark horse 🐴 But this could be a dark horse with lots of potential
2 · Reply
SQUEAKSBANDIT
SQUEAKSBANDIT Sep. 24 at 3:13 PM
$BCYC been awhile since it stuck its head above 7.50 continues up or flattens out back under $7
1 · Reply
SQUEAKSBANDIT
SQUEAKSBANDIT Sep. 17 at 3:40 AM
$BCYC what are you guys thinking data before or after oct 31
2 · Reply
eladfff
eladfff Sep. 10 at 9:44 PM
$BCYC Cutting 25% of workforce but increasing board size by 25%. Ok. Nice round numbers anyway. Like this nice round -50% YTD. With green XBI and IBB. Doesn't even include the December Disaster.
0 · Reply
nikitatrades
nikitatrades Sep. 9 at 1:49 PM
$BCYC #BicycleTx's lead drug, zelenectide, shows promising efficacy (45% ORR) & a safer profile vs. PADCEV in bladder cancer, with less neuropathy & skin toxicity. Pivotal Phase II/III data readout & FDA update due Q4. Strong cash position ($700M+) into 2028. 🚴‍♂️🩺 #Biotech
0 · Reply
bigtuna7
bigtuna7 Sep. 8 at 1:57 PM
$BCYC Looks to be basing, not getting my hopes up.... @SmartestMoney shine some light back on the bike!
1 · Reply
Strangperson
Strangperson Sep. 4 at 4:21 PM
0 · Reply
NVDAMillionaire
NVDAMillionaire Sep. 4 at 12:17 PM
$BCYC Great piece that accurately captures BCYC's current position. So if you want to refresh your understanding of BCYC or learn about BCYC for the first time, this is essential reading. https://beyondspx.com/quote/BCYC/bicycle-therapeutics-pedaling-towards-precision-oncology-with-a-differentiated-platform-nasdaq-bcyc#analysis
0 · Reply
eladfff
eladfff Sep. 2 at 6:36 PM
$BCYC Another $0.50+ fade
0 · Reply
eladfff
eladfff Sep. 2 at 6:35 PM
$BCYC fade through today's AND Friday's gains, ha!
0 · Reply
eladfff
eladfff Aug. 28 at 6:40 PM
$BCYC fades almost every single day. The Daily Fade. Has closed closer to its low than its high 25 of the last 29 sessions
0 · Reply
Stmkr
Stmkr Aug. 28 at 1:45 AM
$BCYC https://pmc.ncbi.nlm.nih.gov/articles/PMC11983102/
0 · Reply